Januar Wibawa Martha1, Raymond Pranata2, Michael Anthonius Lim3, Arief Wibowo4, Mohammad Rizki Akbar5. 1. Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Padjadjaran, Rumah Sakit Umum Pusat Hasan Sadikin, Bandung, Indonesia. Electronic address: jwmartha@gmail.com. 2. Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Padjadjaran, Rumah Sakit Umum Pusat Hasan Sadikin, Bandung, Indonesia; Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia. Electronic address: raymond_pranata@hotmail.com. 3. Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia. Electronic address: lim.michael.a@gmail.com. 4. Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Padjadjaran, Rumah Sakit Umum Pusat Hasan Sadikin, Bandung, Indonesia. Electronic address: ariefwibowo.doc@gmail.com. 5. Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Padjadjaran, Rumah Sakit Umum Pusat Hasan Sadikin, Bandung, Indonesia. Electronic address: m.r.akbar@unpad.ac.id.
Abstract
BACKGROUND: This study aims to investigate whether the active prescription of low-dose aspirin during or prior to hospitalization affects mortality in COVID-19 patients. Aspirin is often prescribed for secondary prevention in patients with cardiovascular disease and other comorbidities that might increase mortality, thus, may falsely demonstrate increased mortality. To reduce bias, we only enrolled studies that performed the adjusted analysis. METHODS: A systematic literature search was performed using PubMed, Scopus, Embase, and Clinicaltrials.gov from the inception of the database up until 16 April 2021. The exposure was active prescription of low-dose aspirin during or prior to hospitalization. The primary outcome was mortality. The pooled adjusted effect estimate was reported as relative risk (RR). RESULTS: There were 6 eligible studies that were included in this meta-analysis, comprising of 13,993 patients. The studies have a low-moderate risk of bias based on Newcastle-Ottawa Scale. Meta-analysis indicates that low-dose aspirin use was independently associated with reduced mortality (RR 0.46 [0.35, 0.61], p < 0.001; I2: 36.2%). Subgroup analysis on in-hospital low-dose aspirin administration also showed statistically significant mortality reduction (RR 0.39 [0.16, 0.96], p < 0.001; I2: 47.0%). CONCLUSION: Low-dose aspirin use is independently associated with reduced mortality in patients with COVID-19 with a low certainty of evidence. PROSPERO: CRD42021249440.
BACKGROUND: This study aims to investigate whether the active prescription of low-dose aspirin during or prior to hospitalization affects mortality in COVID-19patients. Aspirin is often prescribed for secondary prevention in patients with cardiovascular disease and other comorbidities that might increase mortality, thus, may falsely demonstrate increased mortality. To reduce bias, we only enrolled studies that performed the adjusted analysis. METHODS: A systematic literature search was performed using PubMed, Scopus, Embase, and Clinicaltrials.gov from the inception of the database up until 16 April 2021. The exposure was active prescription of low-dose aspirin during or prior to hospitalization. The primary outcome was mortality. The pooled adjusted effect estimate was reported as relative risk (RR). RESULTS: There were 6 eligible studies that were included in this meta-analysis, comprising of 13,993 patients. The studies have a low-moderate risk of bias based on Newcastle-Ottawa Scale. Meta-analysis indicates that low-dose aspirin use was independently associated with reduced mortality (RR 0.46 [0.35, 0.61], p < 0.001; I2: 36.2%). Subgroup analysis on in-hospital low-dose aspirin administration also showed statistically significant mortality reduction (RR 0.39 [0.16, 0.96], p < 0.001; I2: 47.0%). CONCLUSION: Low-dose aspirin use is independently associated with reduced mortality in patients with COVID-19 with a low certainty of evidence. PROSPERO: CRD42021249440.
Authors: Muhammad B Malik; Samar A Amer; Eric Merrell; Ronald Russo; Jeffrey B Riley; Austin Scro; Elizabeth James; Anderson Anuforo; Soumya Adhikari; Rosalie Siciliano; Philip Chebaya; Edward Darling; Michael Kuhn; Gary Nieman; Ahmed Shawkat; Hani Aiash Journal: Health Sci Rep Date: 2022-07-11
Authors: Francesc Formiga; Manuel Rubio-Rivas; José María Mora-Luján; Samara Campos Escudero; Rosa Fernandez Madera Martinez; Manuel Mendez-Bailón; Pedro Durán-Del Campo; Andrea Riaño Pérez; Francisco-Javier García-Sánchez; José Nicolás Alcalá-Pedrajas; Sergio Arnedo Hernández; Almudena Hernández Milian; Ana Latorre Díez; Ricardo Gil Sánchez; Ramon Boixeda; Julio Vicente; Begoña Cortes; Carmen Mella Pérez; María Esther Guisado Espartero; José López Castro; Santiago Rodríguez Suárez; Jose F Varona; Ricardo Gomez-Huelgas; Jose Manuel Ramos-Rincón Journal: Intern Emerg Med Date: 2021-11-29 Impact factor: 5.472
Authors: Udaya S Tantry; Karsten Schror; Eliano Pio Navarese; Young-Hoon Jeong; Jacek Kubica; Kevin P Bliden; Paul A Gurbel Journal: J Exp Pharmacol Date: 2021-12-07
Authors: Brit Long; Summer Chavez; Brandon M Carius; William J Brady; Stephen Y Liang; Alex Koyfman; Michael Gottlieb Journal: Am J Emerg Med Date: 2022-03-26 Impact factor: 4.093
Authors: Heba Wagih Abdelwahab; Shaker Wagih Shaltout; Hazem A Sayed Ahmed; Ahmed Mahmoud Fouad; Eric Merrell; Jeffrey B Riley; Rasha Salama; Ahmed Gharib Abdelrahman; Edward Darling; Ghada Fadel; Mohamed S A Elfar; Khaled Sabry; Jaffer Shah; Hossam Amin; Gary F Nieman; Adel Mishriky; Hani Aiash Journal: Clin Drug Investig Date: 2021-07-30 Impact factor: 2.859